I would gladly take the ColoGuard test, so I do not personally need to be convinced of its worth. However, I don’t think ColoGuard, as currently configured, can be a major commercial success.
For that to happen, third-party payers would have to insist on ColoGuard as a first-line option before any non-high-risk patient were reimbursed for a colonoscopy. Given the tepid data from the DeeP-C study, I can’t see the payers taking such a stand.
Market Data 
Markets 
AI
